Spero Non Currrent Assets Other vs Net Receivables Analysis

SPRO Stock

USD 1.16 0.03 2.52%

Spero Therapeutics financial indicator trend analysis is much more than just breaking down Spero Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spero Therapeutics is a good investment. Please check the relationship between Spero Therapeutics Non Currrent Assets Other and its Net Receivables accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

Non Currrent Assets Other vs Net Receivables

Non Currrent Assets Other vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spero Therapeutics Non Currrent Assets Other account and Net Receivables. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Spero Therapeutics' Non Currrent Assets Other and Net Receivables is 0.96. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Spero Therapeutics, assuming nothing else is changed. The correlation between historical values of Spero Therapeutics' Non Currrent Assets Other and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Spero Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Non Currrent Assets Other i.e., Spero Therapeutics' Non Currrent Assets Other and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Net Receivables

Most indicators from Spero Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spero Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.At this time, Spero Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 25th of November 2024, Enterprise Value Multiple is likely to grow to 0.26, while Selling General Administrative is likely to drop about 21.3 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	106.2M	79.1M	75.3M	67.0M
Cost Of Revenue	1.1M	1.5M	367K	348.7K

Total Operating Expenses Cost Of Revenue

Spero Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.63	0.8	0.95	0.63	0.94	0.82	0.53	-0.86	-0.9	0.01	0.87	0.75	0.67	0.61	0.94	0.51	0.76	0.7	0.79	0.95	0.77	0.8	0.88	-0.74	0.99
Other Current Liab	0.63		0.62	0.61	0.32	0.63	0.84	0.14	-0.41	-0.58	0.34	0.44	0.48	0.38	0.66	0.67	0.2	0.41	0.38	0.63	0.62	0.48	0.59	0.73	-0.48	0.63
Total Current Liabilities	0.8	0.62		0.67	0.53	0.64	0.67	0.69	-0.57	-0.83	0.0	0.59	0.82	0.78	0.37	0.59	0.68	0.82	0.64	0.42	0.85	0.79	0.62	0.79	-0.57	0.73
Total Stockholder Equity	0.95	0.61	0.67		0.4	0.99	0.77	0.43	-0.79	-0.78	0.17	0.8	0.7	0.63	0.57	0.94	0.44	0.63	0.48	0.73	0.86	0.58	0.82	0.76	-0.73	0.95
Other Liab	0.63	0.32	0.53	0.4		0.39	0.52	0.47	-0.7	-0.75	-0.42	0.69	0.46	0.41	0.43	0.58	0.41	0.7	0.98	0.68	0.68	0.9	0.37	0.71	-0.39	0.65
Net Tangible Assets	0.94	0.63	0.64	0.99	0.39		0.78	0.36	-0.8	-0.76	0.22	0.81	0.64	0.56	0.62	0.95	0.36	0.58	0.47	0.74	0.85	0.55	0.76	0.76	-0.82	0.95
Property Plant And Equipment Net	0.82	0.84	0.67	0.77	0.52	0.78		0.27	-0.68	-0.81	-0.09	0.72	0.6	0.48	0.84	0.83	0.28	0.61	0.59	0.83	0.86	0.65	0.62	0.94	-0.59	0.81
Current Deferred Revenue	0.53	0.14	0.69	0.43	0.47	0.36	0.27		-0.46	-0.7	-0.24	0.43	0.9	0.93	-0.13	0.31	0.96	0.9	0.6	0.14	0.56	0.76	0.38	0.44	-0.36	0.46
Net Debt	-0.86	-0.41	-0.57	-0.79	-0.7	-0.8	-0.68	-0.46		0.87	0.2	-1.0	-0.56	-0.49	-0.62	-0.88	-0.37	-0.67	-0.73	-0.69	-0.84	-0.73	-0.73	-0.79	0.66	-0.89
Retained Earnings	-0.9	-0.58	-0.83	-0.78	-0.75	-0.76	-0.81	-0.7	0.87		0.28	-0.87	-0.8	-0.74	-0.61	-0.82	-0.61	-0.92	-0.83	-0.68	-0.96	-0.9	-0.69	-0.93	0.64	-0.89
Accounts Payable	0.01	0.34	0.0	0.17	-0.42	0.22	-0.09	-0.24	0.2	0.28		-0.21	-0.06	-0.05	-0.18	0.08	-0.11	-0.32	-0.41	-0.11	-0.19	-0.3	0.12	-0.25	-0.28	0.02
Cash	0.87	0.44	0.59	0.8	0.69	0.81	0.72	0.43	-1.0	-0.87	-0.21		0.54	0.46	0.67	0.88	0.33	0.65	0.73	0.7	0.86	0.72	0.73	0.82	-0.66	0.9
Non Current Assets Total	0.75	0.48	0.82	0.7	0.46	0.64	0.6	0.9	-0.56	-0.8	-0.06	0.54		0.99	0.14	0.57	0.93	0.91	0.61	0.42	0.73	0.79	0.55	0.66	-0.56	0.68
Non Currrent Assets Other	0.67	0.38	0.78	0.63	0.41	0.56	0.48	0.93	-0.49	-0.74	-0.05	0.46	0.99		0.0	0.47	0.96	0.89	0.56	0.32	0.65	0.75	0.49	0.56	-0.51	0.6
Other Assets	0.61	0.66	0.37	0.57	0.43	0.62	0.84	-0.13	-0.62	-0.61	-0.18	0.67	0.14	0.0		0.74	-0.21	0.29	0.42	0.73	0.71	0.37	0.47	0.8	-0.45	0.65
Cash And Short Term Investments	0.94	0.67	0.59	0.94	0.58	0.95	0.83	0.31	-0.88	-0.82	0.08	0.88	0.57	0.47	0.74		0.28	0.6	0.62	0.85	0.88	0.65	0.78	0.84	-0.74	0.97
Net Receivables	0.51	0.2	0.68	0.44	0.41	0.36	0.28	0.96	-0.37	-0.61	-0.11	0.33	0.93	0.96	-0.21	0.28		0.84	0.55	0.17	0.49	0.72	0.35	0.4	-0.36	0.44
Common Stock Shares Outstanding	0.76	0.41	0.82	0.63	0.7	0.58	0.61	0.9	-0.67	-0.92	-0.32	0.65	0.91	0.89	0.29	0.6	0.84		0.81	0.48	0.83	0.92	0.51	0.76	-0.54	0.71
Non Current Liabilities Total	0.7	0.38	0.64	0.48	0.98	0.47	0.59	0.6	-0.73	-0.83	-0.41	0.73	0.61	0.56	0.42	0.62	0.55	0.81		0.69	0.75	0.96	0.43	0.77	-0.45	0.71
Other Current Assets	0.79	0.63	0.42	0.73	0.68	0.74	0.83	0.14	-0.69	-0.68	-0.11	0.7	0.42	0.32	0.73	0.85	0.17	0.48	0.69		0.74	0.63	0.56	0.8	-0.52	0.83
Other Stockholder Equity	0.95	0.62	0.85	0.86	0.68	0.85	0.86	0.56	-0.84	-0.96	-0.19	0.86	0.73	0.65	0.71	0.88	0.49	0.83	0.75	0.74		0.82	0.72	0.95	-0.69	0.93
Total Liab	0.77	0.48	0.79	0.58	0.9	0.55	0.65	0.76	-0.73	-0.9	-0.3	0.72	0.79	0.75	0.37	0.65	0.72	0.92	0.96	0.63	0.82		0.51	0.81	-0.53	0.75
Deferred Long Term Liab	0.8	0.59	0.62	0.82	0.37	0.76	0.62	0.38	-0.73	-0.69	0.12	0.73	0.55	0.49	0.47	0.78	0.35	0.51	0.43	0.56	0.72	0.51		0.65	-0.33	0.8
Property Plant And Equipment Gross	0.88	0.73	0.79	0.76	0.71	0.76	0.94	0.44	-0.79	-0.93	-0.25	0.82	0.66	0.56	0.8	0.84	0.4	0.76	0.77	0.8	0.95	0.81	0.65		-0.61	0.87
Preferred Stock Total Equity	-0.74	-0.48	-0.57	-0.73	-0.39	-0.82	-0.59	-0.36	0.66	0.64	-0.28	-0.66	-0.56	-0.51	-0.45	-0.74	-0.36	-0.54	-0.45	-0.52	-0.69	-0.53	-0.33	-0.61		-0.74
Total Current Assets	0.99	0.63	0.73	0.95	0.65	0.95	0.81	0.46	-0.89	-0.89	0.02	0.9	0.68	0.6	0.65	0.97	0.44	0.71	0.71	0.83	0.93	0.75	0.8	0.87	-0.74

Click cells to compare fundamentals

Spero Therapeutics Account Relationship Matchups

Spero Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	106.1M	153.5M	171.1M	124.8M	182.4M	119.9M
Other Current Liab	21.6M	11.3M	13.0M	8.8M	6.3M	10.2M
Total Current Liabilities	26.7M	14.3M	18.7M	21.6M	37.2M	18.6M
Total Stockholder Equity	74.6M	132.0M	88.3M	75.9M	106.9M	84.2M
Other Liab	249K	177K	58.1M	22.3M	25.6M	26.9M
Net Tangible Assets	74.6M	132.0M	88.3M	75.9M	87.3M	70.9M
Property Plant And Equipment Net	7.1M	8.8M	7.6M	5.5M	4.2M	4.8M
Net Debt	(24.2M)	(77.4M)	(105.2M)	(102.5M)	(70.8M)	(74.3M)
Retained Earnings	(199.4M)	(277.7M)	(367.5M)	(413.9M)	(391.1M)	(371.5M)
Accounts Payable	4.1M	1.2M	1.1M	617K	1.4M	1.6M
Cash	29.7M	85.2M	112.6M	109.1M	76.3M	67.3M
Non Current Assets Total	24.1M	26.5M	13.2M	15.7M	51.2M	53.7M
Non Currrent Assets Other	16.9M	17.8M	5.6M	10.2M	47.0M	49.4M
Other Assets	3.5M	5.5M	5.6M	5.7M	1.0	0.95
Cash And Short Term Investments	82.0M	126.9M	146.4M	109.1M	76.3M	92.8M
Net Receivables	8.5M	6.2M	2.6M	1.1M	50.7M	53.2M
Common Stock Shares Outstanding	18.2M	22.4M	30.9M	37.6M	53.0M	55.6M
Liabilities And Stockholders Equity	106.1M	153.5M	171.1M	124.8M	182.4M	119.9M
Non Current Liabilities Total	4.9M	7.1M	64.1M	27.2M	38.3M	40.3M
Other Current Assets	4.8M	12.1M	17.7M	3.4M	4.2M	6.5M
Other Stockholder Equity	274.0M	409.7M	455.7M	489.8M	497.9M	302.9M
Total Liab	31.5M	21.4M	82.8M	48.9M	75.5M	79.3M
Property Plant And Equipment Gross	7.1M	8.8M	10.4M	8.7M	7.8M	6.0M
Total Current Assets	82.0M	126.9M	157.9M	109.1M	131.2M	101.2M
Accumulated Other Comprehensive Income	(28K)	16K	(7K)	(2K)	(2.3K)	(2.4K)
Short Term Debt	928K	1.9M	2.7M	3.4M	3.4M	1.9M
Property Plant Equipment	7.1M	1.7M	7.6M	5.5M	6.3M	3.9M
Common Stock	19K	29K	32K	52K	53K	50.4K
Inventory	(13.4M)	(12.2M)	(361K)	(4.5M)	1.0	1.05
Net Invested Capital	74.6M	132.0M	88.3M	75.9M	106.9M	106.5M
Net Working Capital	68.8M	124.8M	139.2M	91.9M	94.1M	112.3M

Pair Trading with Spero Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Spero Stock

0.66	ME	23Andme Holding	Pair Corr
0.74	VALN	Valneva SE ADR	Pair Corr

Moving against Spero Stock

0.54

KZR

Kezar Life Sciences

Pair Corr

The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.

The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:

How To Invest In Spero

Details

Is Spero Stock a good investment?

Details

What is Spero Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.753

Earnings Share

0.08

Revenue Per Share

2.223

Quarterly Revenue Growth

2.754

Return On Assets

0.1048

The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Spero Non Currrent Assets Other vs Net Receivables Analysis

Non Currrent Assets Other vs Net Receivables

Non Currrent Assets Other vs Net Receivables Correlation Analysis

Correlation Coefficient

Non Currrent Assets Other

Net Receivables

Spero Therapeutics fundamental ratios Correlations

Spero Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Spero Therapeutics fundamental ratios Accounts

Pair Trading with Spero Therapeutics

Moving together with Spero Stock

Moving against Spero Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Non Currrent Assets Other	+ 0.99	Non Current Assets Total
Non Current Liabilities Total	+ 0.98	Other Liab
Total Current Assets	+ 0.97	Cash And Short Term Investments
Net Receivables	+ 0.96	Current Deferred Revenue

Cash	- 1.0	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Total Liab	- 0.9	Retained Earnings
Retained Earnings	- 0.9	Total Assets